Cargando…
Intracortical Administration of the Complement C3 Receptor Antagonist Trifluoroacetate Modulates Microglia Reaction after Brain Injury
Worldwide, millions of individuals suffer an ischemic stroke each year, causing major disability, especially in the elderly, where stroke is the number one cause of disability. However, to date, no effective therapy exists that targets the functional recovery after stroke. After necrosis, neuroinfla...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877989/ https://www.ncbi.nlm.nih.gov/pubmed/31814819 http://dx.doi.org/10.1155/2019/1071036 |
_version_ | 1783473452068372480 |
---|---|
author | Surugiu, Roxana Catalin, Bogdan Dumbrava, Danut Gresita, Andrei Olaru, Denisa Greta Hermann, Dirk M. Popa-Wagner, Aurel |
author_facet | Surugiu, Roxana Catalin, Bogdan Dumbrava, Danut Gresita, Andrei Olaru, Denisa Greta Hermann, Dirk M. Popa-Wagner, Aurel |
author_sort | Surugiu, Roxana |
collection | PubMed |
description | Worldwide, millions of individuals suffer an ischemic stroke each year, causing major disability, especially in the elderly, where stroke is the number one cause of disability. However, to date, no effective therapy exists that targets the functional recovery after stroke. After necrosis, neuroinflammation is a common feature of the acute stroke and a major obstacle to tissue restoration. In the lesioned area, the dying neurons release chemotactic signals, such as fractalkine/CX3CL1, which evoke “eat-me” signals that are recognized by microglia expressing complement C3a receptor (C3aR), resulting in phagocytosis of the dying but still viable neurons, known as secondary phagocytosis. Using a mouse model of stroke and two-photon microscopy, we aimed to attenuate poststroke phagocytosis of the dying but still viable neurons by using SB 290157, an antagonist of C3aR. We found that intracortical administration of SB 290157 reduced the number of inflammatory microglial cells expressing ED1 and Iba1 antigens at the lesion site. We could show, in vivo, that two days after a needle-induced cortical lesion there were less microglial cells present around the injury site, displaying less high-order branches and an increase in the lower order ones, suggesting an attenuated phagocytic phenotype in treated animals as compared with controls. We conclude that the C3aR antagonist, SB 290157, may be used in the future to limit the neuronal death by limiting secondary phagocytosis after stroke. |
format | Online Article Text |
id | pubmed-6877989 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-68779892019-12-08 Intracortical Administration of the Complement C3 Receptor Antagonist Trifluoroacetate Modulates Microglia Reaction after Brain Injury Surugiu, Roxana Catalin, Bogdan Dumbrava, Danut Gresita, Andrei Olaru, Denisa Greta Hermann, Dirk M. Popa-Wagner, Aurel Neural Plast Research Article Worldwide, millions of individuals suffer an ischemic stroke each year, causing major disability, especially in the elderly, where stroke is the number one cause of disability. However, to date, no effective therapy exists that targets the functional recovery after stroke. After necrosis, neuroinflammation is a common feature of the acute stroke and a major obstacle to tissue restoration. In the lesioned area, the dying neurons release chemotactic signals, such as fractalkine/CX3CL1, which evoke “eat-me” signals that are recognized by microglia expressing complement C3a receptor (C3aR), resulting in phagocytosis of the dying but still viable neurons, known as secondary phagocytosis. Using a mouse model of stroke and two-photon microscopy, we aimed to attenuate poststroke phagocytosis of the dying but still viable neurons by using SB 290157, an antagonist of C3aR. We found that intracortical administration of SB 290157 reduced the number of inflammatory microglial cells expressing ED1 and Iba1 antigens at the lesion site. We could show, in vivo, that two days after a needle-induced cortical lesion there were less microglial cells present around the injury site, displaying less high-order branches and an increase in the lower order ones, suggesting an attenuated phagocytic phenotype in treated animals as compared with controls. We conclude that the C3aR antagonist, SB 290157, may be used in the future to limit the neuronal death by limiting secondary phagocytosis after stroke. Hindawi 2019-11-14 /pmc/articles/PMC6877989/ /pubmed/31814819 http://dx.doi.org/10.1155/2019/1071036 Text en Copyright © 2019 Roxana Surugiu et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Surugiu, Roxana Catalin, Bogdan Dumbrava, Danut Gresita, Andrei Olaru, Denisa Greta Hermann, Dirk M. Popa-Wagner, Aurel Intracortical Administration of the Complement C3 Receptor Antagonist Trifluoroacetate Modulates Microglia Reaction after Brain Injury |
title | Intracortical Administration of the Complement C3 Receptor Antagonist Trifluoroacetate Modulates Microglia Reaction after Brain Injury |
title_full | Intracortical Administration of the Complement C3 Receptor Antagonist Trifluoroacetate Modulates Microglia Reaction after Brain Injury |
title_fullStr | Intracortical Administration of the Complement C3 Receptor Antagonist Trifluoroacetate Modulates Microglia Reaction after Brain Injury |
title_full_unstemmed | Intracortical Administration of the Complement C3 Receptor Antagonist Trifluoroacetate Modulates Microglia Reaction after Brain Injury |
title_short | Intracortical Administration of the Complement C3 Receptor Antagonist Trifluoroacetate Modulates Microglia Reaction after Brain Injury |
title_sort | intracortical administration of the complement c3 receptor antagonist trifluoroacetate modulates microglia reaction after brain injury |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877989/ https://www.ncbi.nlm.nih.gov/pubmed/31814819 http://dx.doi.org/10.1155/2019/1071036 |
work_keys_str_mv | AT surugiuroxana intracorticaladministrationofthecomplementc3receptorantagonisttrifluoroacetatemodulatesmicrogliareactionafterbraininjury AT catalinbogdan intracorticaladministrationofthecomplementc3receptorantagonisttrifluoroacetatemodulatesmicrogliareactionafterbraininjury AT dumbravadanut intracorticaladministrationofthecomplementc3receptorantagonisttrifluoroacetatemodulatesmicrogliareactionafterbraininjury AT gresitaandrei intracorticaladministrationofthecomplementc3receptorantagonisttrifluoroacetatemodulatesmicrogliareactionafterbraininjury AT olarudenisagreta intracorticaladministrationofthecomplementc3receptorantagonisttrifluoroacetatemodulatesmicrogliareactionafterbraininjury AT hermanndirkm intracorticaladministrationofthecomplementc3receptorantagonisttrifluoroacetatemodulatesmicrogliareactionafterbraininjury AT popawagneraurel intracorticaladministrationofthecomplementc3receptorantagonisttrifluoroacetatemodulatesmicrogliareactionafterbraininjury |